J&J is the most admired pharma company, according to Fortune's annual corporate poll, for the fourth year in a row and comes in at No. 13 among all…

​​​​​​​Gilead might not enjoy suffering its recent, severe hep C revenue downfall, but according to one analyst, the rest of biopharma stands to benefit from…

Pfizer scored new Crohn’s data that could give its Remicade biosimilar, Inflectra, more oomph for its market-share fight, one of the first U.S. head-to-heads…

AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint…

Celgene’s late-stage pill, ozanimod, could hit $2b in sales and add pressure to an already competitive oral MS market, analysts say.

AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-…

Stada said it has a third suitor in the mix to buy the company, and Bernstein analyst Ronny Gal thinks he may know who it is.

The impending approval of Momenta's copy of Teva’s long-acting version of blockbuster Copaxone is now expected to be delayed.

Roche’s Genentech has sued Amgen for not giving up the info Genentech experts need to mount a patent infringement attack on Amgen’s biosimilar for Avastin, its…